NFKB1 and breast cancer: It also was shown in a small study involving patients with locally advanced breast cancer that tumor levels of nuclear (activated) NF-κB could be used to distinguish between responders and nonresponders to neoadjuvant anthracycline- and/or taxane-based chemotherapy regimens [45].